healthcare products, which operates in four segments: Diagnostics, Medical Devices, Nutritionals and Generic Pharmaceuticals . On January 22, 2014, the company reported fourth quarter earnings of $0.58 per share, which was in-line
LONDON, April 16 (Reuters) - Reckitt Benckiser Group on Wednesday reported a 4 percent rise in like-for-like sales at constant currency rates, excluding its shrinking pharmaceuticals business, and said it was on track to achieve its full-year targets.
By Stephen Simpson, CFA : Lexicon Pharmaceuticals ( LXRX ) continues to generate data on its SGLT-1/2 inhibitor LX4211 that suggest this is an effective and promising medication
Teva Pharmaceutical Industries ( TEVA -1.9% ) launches a generic equivalent of the insomnia drug Lunesta (eszopiclone) in the U.S. Sunovion Pharmaceuticals sells the branded product. Domestic sales are ~$850M. Post your comment!
Shares of RNA interference firm Tekmira Pharmaceuticals ( TKMR -14.5% ) continue their slide in early trading. Prices have cratered 60% since the 6x run-up peaked at $31.48
By Jason Napodano : Immune Pharmaceuticals ( OTCQX:IMNP ) is developing bertilimumab, a first-in-class fully human monoclonal antibody that targets eotaxin-1, a
The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover.
By Kevin Quon : Pharmaceutical companies with recently commercialized products can often ..... launched a new treatment option is Ironwood Pharmaceuticals ( IRWD ) . Ironwood Pharmaceuticals is a developing company looking to lead in
hometown of San Diego. San Diego-based Idec Pharmaceuticals was acquired by Biogen in 2003 and it also has ..... partnership with Carlsbad-based biotech company Isis Pharmaceuticals ( ISIS ). Founded in 1978 , Biogen Idec has
would put the current stock price close to our estimate. The strength in J&J's most competitive division-- pharmaceuticals --reinforces our conviction in the company's wide moat. Based on the strong quarterly results, J&J slightly